The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

CHEMBL2062137     (2S)-1-[(2S,4S)-2-hydroxy-4- [[(1R,2R)-2...

Synonyms: AKOS016007841, AC1L4BH9, AK105055, L-754394, L-754,394, ...
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of AIDS096249

  • Mechanism-based inactivation of human liver P450 3A4 by L-754,394, a Merck compound synthesized as a potential HIV protease inhibitor, was investigated using recombinant P450 3A4 [1].
  • L-754,394 is a potent and specific inhibitor of the HIV-1 encoded protease that is essential for the maturation of the infectious virus [2].
 

High impact information on AIDS096249

  • Mechanism-based inactivation of cytochrome P450 3A4 by L-754,394 [1].
  • The major and minor products formed during the inactivation of P450 3A4 were the monohydroxylated and the dihydrodiol metabolites of L-754,394, respectively [1].
  • Collectively, these results are taken to indicate that L-754,394 undergoes cytochrome P450-dependent oxidation of the fused furan ring system, leading to the formation of chemically-reactive intermediates [3].
  • In vitro studies on the metabolic activation of the furanopyridine L-754,394, a highly potent and selective mechanism-based inhibitor of cytochrome P450 3A4 [3].
  • When L-754,394 was incubated with monkey liver microsomes, the corresponding dihydrofurandiol was identified as a metabolite by liquid chromatography-tandem mass spectrometry [3].
 

Biological context of AIDS096249

 

Associations of AIDS096249 with other chemical compounds

 

Gene context of AIDS096249

  • To a lesser extent, L-754,394 also was an inactivator of CYP 2D6, for which the corresponding values for Kl, kinact and partition ratio were 32 microM, 0.18 min-1 and 40, respectively [6].
  • In the present studies, L-754,394 was demonstrated to undergo NADPH-dependent metabolic activation in hepatic microsomal preparations from rats, dogs, rhesus monkeys, and humans to electrophilic intermediates which became bound covalently to cellular proteins [3].
 

Analytical, diagnostic and therapeutic context of AIDS096249

References

  1. Mechanism-based inactivation of cytochrome P450 3A4 by L-754,394. Lightning, L.K., Jones, J.P., Friedberg, T., Pritchard, M.P., Shou, M., Rushmore, T.H., Trager, W.F. Biochemistry (2000) [Pubmed]
  2. Time- and dose-dependent pharmacokinetics of L-754,394, an HIV protease inhibitor, in rats, dogs and monkeys. Lin, J.H., Chiba, M., Chen, I.W., Vastag, K.J., Nishime, J.A., Dorsey, B.D., Michelson, S.R., McDaniel, S.L. J. Pharmacol. Exp. Ther. (1995) [Pubmed]
  3. In vitro studies on the metabolic activation of the furanopyridine L-754,394, a highly potent and selective mechanism-based inhibitor of cytochrome P450 3A4. Sahali-Sahly, Y., Balani, S.K., Lin, J.H., Baillie, T.A. Chem. Res. Toxicol. (1996) [Pubmed]
  4. Route-dependent nonlinear pharmacokinetics of a novel HIV protease inhibitor: involvement of enzyme inactivation. Lin, J.H., Chen, I.W., Chiba, M., Nishime, J.A., Deluna, F.A. Drug Metab. Dispos. (2000) [Pubmed]
  5. Comparative studies to determine the selective inhibitors for P-glycoprotein and cytochrome P4503A4. Achira, M., Suzuki, H., Ito, K., Sugiyama, Y. AAPS PharmSci (1999) [Pubmed]
  6. Potent and selective inactivation of human liver microsomal cytochrome P-450 isoforms by L-754,394, an investigational human immune deficiency virus protease inhibitor. Chiba, M., Nishime, J.A., Lin, J.H. J. Pharmacol. Exp. Ther. (1995) [Pubmed]
 
WikiGenes - Universities